Tatva Chintan Pharma Chem Ltd. will launch a Rs 500-crore initial public offering as the specialty chemical maker aims to fund capex for its facility and promoters look to pare holdings.
Peers
Tatva Chintan competes with Aarti Industries Ltd., Navin Fluorine International Ltd., Alkyl Amines Chemicals Ltd. and Vinati Organics Ltd.
Risks
Unplanned slowdown or shutdowns of manufacturing may impact business, operations and financial conditions.
Increase in raw material costs or loss of suppliers could materially impact operations as it does not have long-term contracts with suppliers.
Country concentration could impact operations as three countries — Germany, the U.S. and China account for 54% of the total revenue.
Inability to complete the capex on time could impact future revenue.
All manufacturing facilities located in Gujarat — Ankleshwar and Dahej —any social or natural disruptions can impact operations.
Does not have long-term contracts with most of its customers.
Watch the interview with Tatva Chintan's Managing Director Chintan Shah.
RECOMMENDED FOR YOU
POPULAR